Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
Objective: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. Methods: The MIC measurement in the presence of β...
Main Authors: | Naoki Kohira, Meredith A. Hackel, Yoshino Ishioka, Miho Kuroiwa, Daniel F. Sahm, Takafumi Sato, Hideki Maki, Yoshinori Yamano |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Journal of Global Antimicrobial Resistance |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716520301843 |
Similar Items
-
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
by: Janet Y. Wu, et al.
Published: (2020-02-01) -
Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019-05-01) -
The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
by: Yasaman Taheri, et al.
Published: (2021-01-01) -
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
by: Giacobbe DR, et al.
Published: (2020-12-01) -
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy
by: Stefano Stracquadanio, et al.
Published: (2021-06-01)